#Class Action #Pomerantz LLP #Unicycive Therapeutics

Pomerantz Law Firm Initiates Class Action Against Unicycive Therapeutics

Pomerantz LLP, a prominent law firm known for its significant involvement in corporate, securities, and antitrust class litigation, has recently announced a class action lawsuit against Unicycive Therapeutics, Inc. This lawsuit specifically targets not only the company but also certain of its high-ranking officials. The class action was filed in the United States District Court for the Northern District of California and is recorded under docket number 25-cv-06923.

The foundation of this legal action is on behalf of a broad class that includes all individuals and entities—excluding the named defendants—who purchased or otherwise acquired securities of Unicycive between March 29, 2024, and June 27, 2025 (referred to as the “Class Period”). The lawsuit seeks restitution for damages that might have arisen due to violations of federal securities laws attributed to the defendants. The Pomerantz firm is pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

Allegations Against Unicycive

Unicycive Therapeutics is a clinical-stage biotechnology firm that focuses on developing and commercializing therapies to satisfy significant medical needs within the United States. Among its pipeline treatments is oxylanthanum carbonate (referred to as